Why Travere Therapeutics Inventory Bolted Increased This Week

What occurred Shares of the uncommon illness specialist Travere Therapeutics( TVTX 3.59%) jumped by a wholesome 19.9% over the primary two and a half days of this holiday-shortened …

59%
OFF

Why Travere Therapeutics Inventory Bolted Increased This Week

2 weeks from now

What occurred Shares of the uncommon illness specialist Travere Therapeutics( TVTX 3.59%) jumped by a wholesome 19.9% over the primary two and a half days of this holiday-shortened …

bizagility.org

9%
OFF

Why Travere Therapeutics Stock Bolted Higher This Week - The …

2 weeks from now

Shares of the rare disease specialist Travere Therapeutics (TVTX) jumped by a healthy 19.9% over the first two and a half days of this holiday-shortened week, according to data provided by S&P Global Market Intelligence. This double-digit gain is noteworthy because most small-cap biotech stocks have struggled in recent trading sessions due to the p...

fool.com

9%
OFF

Why Travere Therapeutics Stock Bolted Higher This Week

2 weeks from now

Feb 23, 2023 · What happened Shares of the rare disease specialist Travere Therapeutics(NASDAQ: TVTX) jumped by a healthy 19.9% over the first two and a half days …

theglobeandmail.com

9%
OFF

Why Travere Therapeutics Stock Bolted Higher This Week

2 weeks from now

Feb 23, 2023 · Shares of the rare disease specialist Travere Therapeutics(NASDAQ: TVTX) jumped by a healthy 19.9% over the first two and a half days of this holiday-shortened week, …

sharewise.com

6%
OFF

Travere (TVTX) Surges 11.6%: Is This An Indication Of Further Gains?

2 weeks from now

Oct 7, 2024 · Travere Therapeutics (TVTX) shares soared 11.6% in the last trading session to close at $15.23. The move was backed by solid volume with far more shares changing hands …

yahoo.com

$7
OFF

What's Going On With Travere Therapeutics Stock?

2 weeks from now

Dec 5, 2023 · Following the company's announcements, Citigroup analyst Carly Kenselaar upgraded Travere Therapeutics from Neutral to Buy and raised the price target from $7 to $10.

businessinsider.com

2%
OFF

Travere Therapeutics (NASDAQ:TVTX) Trading 7.2% Higher

2 weeks from now

Jan 2, 2025 · Travere Therapeutics, Inc. (NASDAQ:TVTX - Get Free Report)'s share price shot up 7.2% on Thursday . The stock traded as high as $18.67 and last traded at $18.67. 606,293 …

marketbeat.com

68%
OFF

Travere Therapeutics (TVTX) Stock Price, News & Analysis

2 weeks from now

1 day ago · Travere Therapeutics has a short interest ratio ("days to cover") of 5.9. Short interest in Travere Therapeutics has recently increased by 17.68%, indicating that investor sentiment …

marketbeat.com

9%
OFF

The Globe And Mail - The Globe And Mail

2 weeks from now

Feb 23, 2023 · What happened Shares of the rare disease specialist Travere Therapeutics(NASDAQ: TVTX) jumped by a healthy 19.9% over the first two and a half days …

theglobeandmail.com

30%
OFF

Travere (TVTX) Stock Up More Than 30% In 3 Months: Here's Why

2 weeks from now

Shares of Travere Therapeutics, Inc. TVTX have rallied 33.3% in the past three months compared with the industry’s increase of 14.5%. In December 2023, the company completed a pre-NDA …

msn.com

$27
OFF

TD Cowen Reiterates Buy On Travere Shares After PARASOL Findings

2 weeks from now

Oct 29, 2024 · The firm also adjusted Travere Therapeutics' valuation to $27 per share and increased its sales expectations for Filspari in IgA Nephropathy (IgAN) to $700 million from …

investing.com

04%
OFF

Why Shares Of Travere Therapeutics Are Slumping Thursday - The …

2 weeks from now

Sep 21, 2023 · Shares of Travere Therapeutics (TVTX 1.04%) were down more than 40% as of noon on Thursday after the company released mixed phase 3 trial results regarding Filspari, …

fool.com

FAQs about Why Travere Therapeutics Inventory Bolted Increased This Week Coupon?

How did Travere Therapeutics (tvtx) perform in the quarter?

Travere Therapeutics, Inc. (NASDAQ:TVTX) reported earnings for the last quarter on Thursday, October 28th. The company earned ($0.59) per share, which was better than analysts' consensus estimate of ($0.72) by $0.13. The business generated $68.20 million in revenue during the quarter, compared to the consensus estimate of $60.93 million. ...

How much will Travere Therapeutics sell in Q4 2024?

SAN DIEGO, Jan. 13, 2025 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc., (NASDAQ: TVTX) today announced that, based on preliminary and unaudited financial data, the Company expects net product sales for the fourth quarter of 2024 to be approximately $74 million. ...

Does Travere therapeutics have a high-value regulatory approval for a rare kidney disease?

Travere Therapeutics won a high-value regulatory approval for a rare kidney disease last Friday. Wall Street analysts think this drug has blockbuster sales potential. You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. ...